Conference Correspondent

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia
Read More
ELEVATE TN: Results of a Phase 3 Study of Acalabrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Read More
Ibrutinib + Venetoclax for First-Line Treatment of CLL: Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
Read More
Polatuzumab Vedotin + Obinutuzumab + Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma
Read More
Effect of Fixed-Duration Venetoclax plus Obinutuzumab on Progression-Free Survival and Minimal Residual Disease Status in Treatment-Naïve Patients with CLL and Comorbidities
Read More
Three-Year Follow-Up of Acalabrutinib and Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL
Read More
Comparison of 3 Rituximab-Containing Regimens as Primary Therapy in Patients with WM
Read More
Patient-Reported Outcomes with Ibrutinib-Rituximab in WM: Results from iNNOVATE
Read More
Evaluation of MRD with Lisocabtagene Maraleucel, a CD19-Directed CAR T Therapy, in Patients with Relapsed/Refractory CLL/SLL
Read More
Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL
Read More
Page 4 of 25
Results 31 - 40 of 242
SUBSCRIBE
Copyright © Amplity Medical Communications. All rights reserved.